Welcome to our dedicated page for Alto Neuroscience SEC filings (Ticker: ANRO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Alto Neuroscience's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Alto Neuroscience's regulatory disclosures and financial reporting.
Smith Nicholas Conrad reported acquisition or exercise transactions in a Form 4 filing for ANRO. The filing lists transactions totaling 200,000 shares. Following the reported transactions, holdings were 200,000 shares.
Alto Neuroscience reported that its Chief Operating Officer, Michael Conick Hanley Jr., received an employee stock option grant. On February 11, 2026, he was awarded options to acquire 131,000 shares of common stock at an exercise price of $16.71 per share.
The options vest over four years: 25% of the underlying shares vest on February 11, 2027, with the remaining shares vesting in equal monthly installments over the following three years, contingent on his continued service with the company.
Alto Neuroscience, Inc. disclosed that one of its directors received a new stock option grant. On 01/02/2026, the director was granted an option to purchase 5,243 shares of Alto Neuroscience common stock at an exercise price of $16.59 per share, expiring on 01/01/2036.
The option vests in four equal quarterly installments during 2026: 1,311 shares on March 31, 1,311 shares on June 30, 1,310 shares on September 30, and 1,311 shares on December 31, subject to the director’s continuous service. The filing notes that this option was issued under the company’s Non-Employee Director Compensation Policy in lieu of $62,000 in cash retainer fees.
Alto Neuroscience director reports new stock option grant. A board member of Alto Neuroscience, Inc. filed a Form 4 reporting receipt of a stock option covering 7,189 shares of common stock on 01/02/2026.
The option was granted under the company’s Non-Employee Director Compensation Policy in lieu of cash retainer fees of $85,000. Vesting is scheduled in four installments during 2026: 1,797 shares on March 31, 1,797 shares on June 30, 1,798 shares on September 30, and 1,797 shares on December 31, contingent on the director’s continuous service through each vesting date.
Alto Neuroscience, Inc. director compensation is disclosed through a new stock option grant. On 01/02/2026, a reporting person serving as a director received an employee stock option to buy 4,228 shares of common stock at an exercise price of $16.59 per share. The option relates to 4,228 underlying common shares and was granted under the company’s Non-Employee Director Compensation Policy in lieu of $50,000 in cash retainer fees. The option vests in four equal installments of 1,057 shares on March 31, 2026, June 30, 2026, September 30, 2026 and December 31, 2026, if the director’s service continues through each vesting date.
Alto Neuroscience, Inc. reported that one of its directors received a grant of stock options. On 01/02/2026, the director was granted 3,806 stock options to purchase Alto Neuroscience common stock. These options were issued under the company’s Non-Employee Director Compensation Policy in lieu of $45,000 in retainer fees.
The options vest in four quarterly installments during 2026, subject to the director’s continued service. 952 options vest on March 31, 2026, 951 options on June 30, 2026, 952 options on September 30, 2026, and 951 options on December 31, 2026. Any unvested portion would not be earned if service ends before the relevant vesting date.
Alto Neuroscience, Inc. has filed a resale registration statement covering up to 8,454,514 shares of common stock for selling stockholders. The shares consist of 3,832,263 outstanding shares and 4,622,251 shares issuable upon exercise of pre-funded warrants from an October 2025 private placement. Alto will not receive proceeds from any stockholder sales, but will receive the $0.0001 per share exercise price if the pre-funded warrants are exercised for cash.
Alto is a clinical-stage biopharmaceutical company using its Precision Psychiatry Platform to develop biomarker-driven treatments for major depressive disorder, bipolar depression, treatment-resistant depression and schizophrenia, with seven clinical-stage assets. The October 2025 private placement raised approximately $50.0 million at $5.914 per share, and Alto reported 31,034,019 shares outstanding as of October 21, 2025 following that financing.
Alto Neuroscience (ANRO) reported Q3 2025 results highlighted by disciplined spending and solid liquidity to fund its clinical pipeline. Cash and cash equivalents were $137.8 million as of September 30, 2025, with total assets of $147.0 million. Net loss was $14.2 million (vs. $16.8 million a year ago) as research and development and general and administrative expenses declined year over year.
Operating cash outflow was $40.3 million for the nine months, reflecting ongoing clinical execution. During the quarter, Alto amended its term loan to up to $75.0 million, drew $20.0 million, and extended maturity to January 1, 2029 with interest-only payments until January 1, 2027. The Wellcome Convertible Grant Agreement remained in place with $2.1 million measured at fair value as of quarter end.
After quarter close, the company completed a private placement issuing 3,832,263 shares and pre-funded warrants for 4,622,251 shares, for $49.9 million in net proceeds. Shares outstanding were 31,066,335 as of November 7, 2025.
Alto Neuroscience, Inc. filed a Form 8-K stating that it reported financial results for the fiscal quarter ended September 30, 2025. The company released these quarterly results in a press release dated November 12, 2025, which is furnished as Exhibit 99.1 and incorporated by reference.
The Form 8-K clarifies that the financial information, including the press release, is being furnished rather than filed under the Exchange Act and is not subject to certain liability provisions, unless specifically incorporated into other SEC filings.
Alto Neuroscience (ANRO): Schedule 13G filed reporting a passive stake by Commodore Capital LP, Commodore Capital Master LP, Robert Egen Atkinson, and Michael Kramarz. The filers beneficially own 3,190,267 shares of common stock, representing 9.8% of the class.
The position includes 1,653,913 common shares and 1,536,354 shares issuable upon exercise of a pre-funded warrant, subject to a Beneficial Ownership Limitation. Ownership percentages are based on 30,908,892 shares outstanding as of October 20, 2025, plus the shares underlying the pre-funded warrant. The filers report shared voting and dispositive power over 3,190,267 shares and certify the securities were not acquired to change or influence control.